BOSENTAN

The U.S. FDA approved bosentan on 20 November 2001. Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH).

Bosentan is used to treat pulmonary arterial hypertension (high blood pressure).

Bosentan is available in two different strengths, 62.5mg and 125mg tablets which can be consumed orally. Your physician will decide the dosage and frequency of this injection based on the severity of your disease and other factors.

The common side effects that are experienced while you are on the treatment are Bosentan headache, oedema, respiratory tract infection, inflamed nose passage, joint pain, irregular heartbeats, diarrhoea and low blood pressure. Report your doctor immediately, if you experience abnormal liver function, anaemia, allergic reaction (skin inflammation, itching and rash).

Inform your doctor if you are allergic to bosentan or any of the ingredients present in them. Inform your doctor if you have any history of liver problems, psoriasis, or hypoglycemia (low blood pressure).

Inform your doctor about your prescribed and non-prescribed medicine and take a proper diet while under medication. It will be helpful for him to treat you based on your previous medical history or make some dose adjustments. It is not recommended for pediatric patients with systemic sclerosis and ulcer disease. It may affect the fertility of the male individual and foetus of the pregnant female individual. So, consult your doctor if you are planning to get pregnant or think you may be pregnant while breastfeeding.

Your doctor will recommend monitoring your blood pressure and haemoglobin level, as bosentan may cause low blood pressure and anaemia as a side effect. Inform your doctor if you have liver disease, are pregnant, are planning to become pregnant, or suspect you may be pregnant before taking this medicine. Bosentan may be contraindicated in patients with liver disease or in pregnant women. Discuss your complete medical history with your doctor before starting this medicine.

Pharmadox Healthcare Ltd., Electronic Medicines Compendium (EMC), [Revised on June 2018] [Accessed on 30th Sep 2023], Bosentan Dr. Reddy's 62.5 mg Film-Coated Tablets - Patient Information Leaflet (PIL) - (emc) (medicines.org.uk) Actelion Pharmaceuticals US, Inc., US Food and Drug Administration, [Revised on Sep 2017], [Accessed on 20th Oct 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf Good and Gilman’s, The pharmacological basis of therapeutics, protein synthesis inhibitors and miscellaneous antibacterial agents, 13th edition, 76, 580-583, 841.